{"title":"Heart rate variability in mental disorders: an umbrella review of meta-analyses.","authors":"Zuxing Wang, Yazhu Zou, Jingwen Liu, Wei Peng, Mingmei Li, Zhili Zou","doi":"10.1038/s41398-025-03339-x","DOIUrl":null,"url":null,"abstract":"<p><p>Heart rate variability (HRV) monitoring is increasingly applied in the realm of mental disorders; however, it remains a subject of controversy. This umbrella review summarizes HRV differences between individuals with mental disorders and healthy controls (HCs), as well as changes in HRV before and after treatment in patients with mental disorders. A literature search was conducted using Medline, PubMed, Embase, and the Cochrane Database. Meta-analyses on HRV changes in patients with mental disorders, as well as meta-analyses comparing HCs and patients with mental disorders were included. We computed the summary effect size using random effects models, along with 95% confidence and prediction intervals. We assessed heterogeneity, p value of the largest study, excess significance bias, and small-study effects. Evidence levels were classified as convincing, highly suggestive, suggestive, weak, or not significant. Twenty-one systematic reviews on HRV, covering 19 mental disorders (53 meta-analyses) and 8 treatment modalities (18 meta-analyses), included 442 primary studies and 34,625. For differences between mental disorders and HCs, evidence was suggestive for 7 (13.2%) pooled analyses, indicating decreased HRV in dementia, PTSD, somatic symptom disorders, functional somatic syndromes, and schizophrenia. For other disorders, including autism spectrum disorder, alcohol use disorder, bipolar disorder, generalized anxiety disorder, insomnia, and major depressive disorder, the evidence was weaker and below the suggestive level. For treatment effects, 5 pooled analyses (27.8%) had weak evidence, indicating altered HRV before and after antipsychotic treatment, repetitive transcranial magnetic stimulation treatment, physiotherapy, and psychotherapy. The credibility of HRV evidence in mental disorders varied across HRV variables and diseases. No two diseases exhibited identical altered HRV patterns, highlighting the potential significance of overall HRV profiles in delineating distinct disorders.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"15 1","pages":"104"},"PeriodicalIF":5.8000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953273/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-025-03339-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Heart rate variability (HRV) monitoring is increasingly applied in the realm of mental disorders; however, it remains a subject of controversy. This umbrella review summarizes HRV differences between individuals with mental disorders and healthy controls (HCs), as well as changes in HRV before and after treatment in patients with mental disorders. A literature search was conducted using Medline, PubMed, Embase, and the Cochrane Database. Meta-analyses on HRV changes in patients with mental disorders, as well as meta-analyses comparing HCs and patients with mental disorders were included. We computed the summary effect size using random effects models, along with 95% confidence and prediction intervals. We assessed heterogeneity, p value of the largest study, excess significance bias, and small-study effects. Evidence levels were classified as convincing, highly suggestive, suggestive, weak, or not significant. Twenty-one systematic reviews on HRV, covering 19 mental disorders (53 meta-analyses) and 8 treatment modalities (18 meta-analyses), included 442 primary studies and 34,625. For differences between mental disorders and HCs, evidence was suggestive for 7 (13.2%) pooled analyses, indicating decreased HRV in dementia, PTSD, somatic symptom disorders, functional somatic syndromes, and schizophrenia. For other disorders, including autism spectrum disorder, alcohol use disorder, bipolar disorder, generalized anxiety disorder, insomnia, and major depressive disorder, the evidence was weaker and below the suggestive level. For treatment effects, 5 pooled analyses (27.8%) had weak evidence, indicating altered HRV before and after antipsychotic treatment, repetitive transcranial magnetic stimulation treatment, physiotherapy, and psychotherapy. The credibility of HRV evidence in mental disorders varied across HRV variables and diseases. No two diseases exhibited identical altered HRV patterns, highlighting the potential significance of overall HRV profiles in delineating distinct disorders.
期刊介绍:
Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.